Condition
Immunoglobulin G4-related Disease
Total Trials
5
Recruiting
2
Active
2
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 2 (1)
Trial Status
Recruiting2
Not Yet Recruiting2
Unknown1
Clinical Trials (5)
Showing 5 of 5 trials
NCT07222553Phase 2Not Yet RecruitingPrimary
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD
NCT06573723Recruiting
Institutional Registry of Rare Diseases
NCT06270524Not ApplicableNot Yet RecruitingPrimary
Study of the C5a/C5aR1 Axis in IgG4-associated Disease: a Potential Therapeutic Target
NCT05901207UnknownPrimary
Diagnostic and Prognostic Biomarkers for IgG4-related Disease.
NCT05681975Recruiting
Immunoglobulin G4 and Immunoglobulin E Antibodies in a Population With Adverse Reactions to Foodstuffs-related Symptoms
Showing all 5 trials